The US FDA has approved bevacizumab-nwgd, a biosimilar, to treat several different types of cancer. Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor.
It prevents VEGF from interacting with its receptors on the surface of endothelial cells and thus prevents angiogenesis, restricting blood supply to tumors. Bevacizumab is indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment Recurrent glioblastoma in adults Metastatic renal cell carcinoma in…
